T2 Biosystems (TTOO) Reaches $4.00 After 7.00% Down Move; Target (TGT) Covered By 6 Bullish Analysts Last Week

August 27, 2017 - By Migdalia James

Among 24 analysts covering Target Corporation (NYSE:TGT), 6 have Buy rating, 3 Sell and 15 Hold. Therefore 25% are positive. Target Corporation had 60 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Hold” rating by BMO Capital Markets on Thursday, July 13. Jefferies maintained Target Corporation (NYSE:TGT) on Tuesday, July 25 with “Hold” rating. The rating was initiated by Gordon Haskett on Tuesday, May 9 with “Sell”. The stock of Target Corporation (NYSE:TGT) earned “Outperform” rating by Cowen & Co on Saturday, August 22. Vetr upgraded Target Corporation (NYSE:TGT) on Wednesday, September 2 to “Strong-Buy” rating. Barclays Capital maintained the stock with “Underweight” rating in Thursday, May 19 report. The firm has “Outperform” rating given on Thursday, February 25 by Cowen & Co. The rating was upgraded by Gordon Haskett to “Hold” on Wednesday, August 16. Telsey Advisory Group maintained it with “Outperform” rating and $78 target in Wednesday, January 18 report. The stock of Target Corporation (NYSE:TGT) has “Neutral” rating given on Thursday, August 18 by Goldman Sachs. See Target Corporation (NYSE:TGT) latest ratings:

18/08/2017 Broker: Bank of America Rating: Buy Old Target: $4.25 New Target: $4.45 Maintain
18/08/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $62 New Target: $67 Maintain
17/08/2017 Broker: M Partners Old Rating: Neutral New Rating: Buy Upgrade
16/08/2017 Broker: Gordon Haskett Old Rating: Sell New Rating: Hold Old Target: $47 New Target: $58 Upgrade
09/08/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $58.0000 Maintain
25/07/2017 Broker: Jefferies Rating: Hold New Target: $59.0000 Maintain
13/07/2017 Broker: Cowen & Co Rating: Hold New Target: $64.0000 Maintain
13/07/2017 Broker: BMO Capital Markets Rating: Hold New Target: $62.0000 Maintain
19/06/2017 Broker: UBS Rating: Hold Maintain
21/06/2017 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade

The stock of T2 Biosystems Inc (NASDAQ:TTOO) is a huge mover today! The stock decreased 2.91% or $0.12 on August 25, reaching $4. About 65,116 shares traded. T2 Biosystems Inc (NASDAQ:TTOO) has declined 60.66% since August 27, 2016 and is downtrending. It has underperformed by 77.36% the S&P500.The move comes after 5 months negative chart setup for the $123.06 million company. It was reported on Aug, 27 by Barchart.com. We have $3.72 PT which if reached, will make NASDAQ:TTOO worth $8.61 million less.

Among 8 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. T2 Biosystems Inc had 14 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Sunday, August 16 by BTIG Research. The firm earned “Buy” rating on Tuesday, October 27 by Canaccord Genuity. The company was upgraded on Wednesday, July 20 by WBB Securities. The stock of T2 Biosystems Inc (NASDAQ:TTOO) has “Buy” rating given on Wednesday, November 2 by Cantor Fitzgerald. Janney Capital downgraded T2 Biosystems Inc (NASDAQ:TTOO) on Tuesday, April 12 to “Neutral” rating. The firm has “Buy” rating given on Tuesday, August 2 by Canaccord Genuity. The company was initiated on Tuesday, July 21 by BTIG Research. BTIG Research upgraded T2 Biosystems Inc (NASDAQ:TTOO) on Thursday, September 3 to “Buy” rating. Morgan Stanley downgraded the stock to “Underweight” rating in Wednesday, March 15 report. Leerink Swann reinitiated T2 Biosystems Inc (NASDAQ:TTOO) on Thursday, November 10 with “Market Perform” rating.

T2 Biosystems, Inc. is an in vitro diagnostics firm engaged in developing a technology platform offering an alternative to diagnostic methodologies. The company has market cap of $123.06 million. The Company’s T2 Magnetic Resonance platform enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). It currently has negative earnings. The Company’s initial development efforts target sepsis, hemostasis and Lyme disease.